Evaluation of Safety and Efficacy of Lorazepam in Patients Having Delirium, Sleep Disorder with Acute Coronary Syndrome

Abstract

Acute coronary syndrome is still a major source of morbidity and mortality all over the world. The standard goal of treatment is to restore blood flow quickly using initial Percutaneous Coronary Intervention (PCI). PCI can enhance short- and long-term results after a myocardial infarction when combined with adequate medical care (MI). Patients with ST Elevation Myocardial Infarction (STEMI) can be treated with fibrinolytic treatment if PCI is not possible due to time constraints. This prospective comparison study was conducted in Vadodara, Gujarat, at a small teaching and general hospital. Sedation medications are the most common treatment for anxiety. All MI patients are given lorazepam every night until they are discharged. Lorazepam is an efficient anti-anxiety medication that can also help with depressive symptoms and insomnia. The study included a total sample size of 235 people. Patients must be over the age of 18 and have good consciousness and hemodynamic stability to be considered. Before patient consent was gained, data was collected using pre-prepared questionnaires. The percentage difference between groups and the 95 percent confidence interval are used to compare primary endpoint data between groups. All statistical analyses were conducted using SPSS Statistics, and all tests were considered statistically significant if the p-value was less than 0.05. For the cardiac events investigated in this trial, placebo was shown to be non-inferior to lorazepam for chest discomfort, delirium, and arrhythmias. The lorazepam group had a significantly higher mean score of first-night sleep satisfaction than the placebo group, indicating that lorazepam can alleviate anxiety and enhance sleep quality in ACS patients during their first night in the hospital.